Jul 16 |
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
|
Jul 15 |
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
|
Jul 15 |
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations
|
Jul 15 |
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
|
Jul 15 |
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
|
Jul 14 |
Got $1,000? 2 Incredible Growth Stocks to Buy and Hold Forever
|
Jul 11 |
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
|
Jul 10 |
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|
Jul 9 |
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
|
Jul 9 |
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
|